Two centuries. Countless innovations. One vision.
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for SpikevaxTM COVID-19 Vaccine in Japan to Moderna
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan
Copyright 1995-2022 Takeda Pharmaceutical Company Limited. All rights reserved.